
    
      This is a study involving a 2-4 week run-in phase followed by a 12 week double blind
      treatment phase. During the run-in phase, subjects receive Flixotide®. In the treatment phase
      subjects will be randomised to one of the two treatment groups and will receive either
      FlutiForm® and placebo inhaler for symbicort® turbohaler® or symbicort® turbohaler® and
      placebo inhaler for Flutiform ® . Efficacy will be assessed by lung function tests, asthma
      symptoms, sleep disturbance due to asthma and rescue medication use. Safety will be assessed
      by adverse events, lab tests, ECGs and vital signs.
    
  